On Friday, November 8, 2019, the ALS Therapy Development Institute (ALS TDI) hosted the 15th Leadership Summit.

Developing a new drug and bringing it all the way through the clinical trial process is a long and difficult task.

In December 2019, the Motor Neuron Disease Association (MNDA) will be holding its annual International Symposium on ALS/MND from December 4th to 6th in Perth, Australia. Fernando Vieira, the Chief Scientific Officer of the ALS Therapy Development Institute (ALS TDI) will be in attendance.

On Friday, 11/8/2019, Brian Wallach received the Stephen Heywood Patients Today Award. The award was

Anelixis Therapeutics, a for-profit clinical-stage development company that brought the drug through trial, announced on Monday, November 18, that they completed a Phase 1 safety and pharmacokinetic study of AT-1501 in healthy subjects and people living with ALS.

The ALS Therapy Development Institute (ALS TDI) is proud to announce the 2019 Leadership Award recipients. The ALS TDI Leadership Awards are presented each year to honor those who lead us in the battle against ALS. This year's recipients include Brian Wallach, Glynis Murray, Lisa Cross Bonahoom, Jamey Spakes and Hugh Macdonnell. The recipients were chosen from nominations made by members of the ALS community.